Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 1.00 |
| ▸ | S1PR3 | Q99500 | 9/20 | 1.00 |
| ▸ | S1PR4 | O95977 | 7/20 | 1.00 |
| ▸ | TNNC1 | P63316 | 6/20 | 1.00 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 1.00 |
| ▸ | SGPL1 | O95470 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | CERS2 | Q96G23 | 1/20 | 1.00 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.78 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.78 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.74 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391728 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL1372656 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3394554 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3389578 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3394797 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3390328 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3392313 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| Fingolimod SCHEMBL7445 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| SCHEMBL3393539 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 | |
| Hydrochloric Acid SCHEMBL8500527 | 0.98 | S1PR1 (1.00) | S1PR1S1PR3S1PR4TNNC1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118845641-A | Fengomod oral liquid composition and application thereof | 苏州华健瑞达医药技术有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20170151195-A1 | Compositions Comprising Sphingosine 1 Phosphate (S1P) Receptor Modulators | NOVARTIS AG (CH) | 2017-06-01 | — | — | US | disclosed |
| US-20170151195-A1 | Compositions Comprising Sphingosine 1 Phosphate (S1P) Receptor Modulators | NOVARTIS AG (CH) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151195-A1 | Compositions Comprising Sphingosine 1 Phosphate (S1P) Receptor Modulators | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR3 4/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.